Inventor · disambiguated record
Anne-Marie Beausoleil
Also filed as: BEAUSOLEIL ANNE-MARIE
32 granted patents·12 pending applications·120 citations·filing 2016–2025
96Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC19UNITY BIOTECHNOLOGY INC14NEUMORA THERAPEUTICS INC5CORVUS PHARMACEUTICALS INC4ANGEL PHARMACEUTICAL CO LTD1
Top patents by PatentIndex Score
44 records- 0198US10526330B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 7, 2020·15 cites·13 claims
- 0298US10100049B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Oct 16, 2018·28 cites·17 claims
- 0397US9725470B2Substituted naphthyridines as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Aug 8, 2017·27 cites·19 claims
- 0495US10028960B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jul 24, 2018·18 cites·13 claims
- 0593US11299492B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 12, 2022·2 cites·13 claims
- 0692US10981892B2Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2020·Granted Apr 20, 2021·2 cites·1 claims
- 0791US9533962B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 3, 2017·6 cites·28 claims
- 0890US2025188055A1Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 0989US12358931B23-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Jul 15, 2025·0 cites·5 claims
- 1089US11110095B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Sep 7, 2021·3 cites·22 claims
- 1189US10519197B1Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Dec 31, 2019·3 cites·14 claims
- 1289US9872855B2(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 23, 2018·5 cites·9 claims
- 1388US11033533B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
- 1487US10172834B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 8, 2019·3 cites·3 claims
- 1586US10717722B2Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jul 21, 2020·2 cites·9 claims
- 1684US10548879B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 4, 2020·2 cites·20 claims
- 1782US12371414B2Methods of treating neurological disordersNEUMORA THERAPEUTICS INC·Filed 2024·Granted Jul 29, 2025·0 cites·6 claims
- 1882US11993580B1Methods of treating neurological disordersNEUMORA THERAPEUTICS INC·Filed 2023·Granted May 28, 2024·0 cites·6 claims
- 1981US2024383884A1Compounds and methods for modulating interleukin-2-inducible t-cell kinaseCORVUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2079US11718616B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Aug 8, 2023·0 cites·7 claims
- 2179US11642332B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted May 9, 2023·0 cites·20 claims
- 2279US11008314B2Compounds and methods for modulating interleukin-2-inducible t-cell kinaseCORVUS PHARMACEUTICALS INC·Filed 2017·Granted May 18, 2021·1 cites·30 claims
- 2378US12221433B2Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2021·Granted Feb 11, 2025·0 cites·1 claims
- 2478US10870652B2Compounds and methods for modulating bruton's tyrosine kinaseCORVUS PHARMACEUTICALS INC·Filed 2017·Granted Dec 22, 2020·2 cites·28 claims
- 2573US2023365534A1Modulators of nlrp3 inflammasome and related products and methodsNEUMORA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2671US11897874B2Compounds and methods for modulating Interleukin-2-inducible T-cell kinaseCORVUS PHARMACEUTICALS INC·Filed 2021·Granted Feb 13, 2024·0 cites·29 claims
- 2771US2025304560A1Modulators of nlrp3 inflammasome and related products and methodsNEUMORA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2868US10745429B2Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Aug 18, 2020·0 cites·15 claims
- 2964US10689416B2Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jun 23, 2020·0 cites·10 claims
- 3063US2025074888A1Pyridazine derivatives as modulators of nlrp3 inflammasome and related methodsNEUMORA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3161US10005740B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jun 26, 2018·0 cites·1 claims
- 3261US2020392105A1Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3361US2020399259A1Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3460US10738042B2Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY·Filed 2019·Granted Aug 11, 2020·0 cites·27 claims
- 3560US9868698B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 16, 2018·0 cites·2 claims
- 3660US2020354336A9Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent CellsUNITY BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 3759US2021070788A1Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3857US11306099B1Compounds and methods for modulating Bruton's Tyrosine KinaseANGEL PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 19, 2022·0 cites·24 claims
- 3957US9433598B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Sep 6, 2016·0 cites·26 claims
- 4056US9670143B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jun 6, 2017·0 cites·2 claims
- 4155US2018193338A1Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Application pending·0 cites
- 4246US10703745B2Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jul 7, 2020·0 cites·18 claims
- 4346US2020360386A1Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 4442US2021379078A1Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 InhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anne-Marie Beausoleil files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →